Please login to the form below
29
Revenue 2017Soliris
The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Soliris was produced by Alexion.
Drug launches to watch in 2019
Analysts predict peak sales of up to $3bn. 5. Ultomiris – Alexion’s follow-up to Soliris. ... The drug matched Soliris for efficacy with a trend towards superiority and has improved dosing.
Alexion targets RNAi with $637m Dicerna deal
Alexion already has a follow-on complement inhibitor to be the next generation replacement for Soliris. ... With Soliris, Alexion has demonstrated the transformative impact of complement inhibition on multiple serious and debilitating diseases.
Alexion adds to pipeline with $1.2bn Syntimmune buy
Alexion is in the midst of a concerted effort to build its pipeline as it prepares for the possible loss of patent protection for Soliris (eculizumab), its biggest-selling product. ... Used to treat paroxysmal nocturnal haemoglobinuria (PNH) and
The year of the blockbuster
These include Juno Therapeutics’ CAR T-cell therapy, lisocabtagene maraleucel, for diffuse large B-cell lymphoma, and Alexion’s next-generation Soliris treatment, ravulizumab, for paroxysmal nocturnal haemoglobinuria.
Alexion uses priority review voucher for Soliris follow-up
Files ravulizumab for paroxysmal nocturnal haemoglobinuria. Alexion is pulling out all the stops to get speedy approval for a follow-up to its rare blood disorder therapy Soliris, using a coveted ... The company has filed ravulizumab ( ALXN1210) for
Data provided by GlobalData
GlobalData is the premier source of research and consulting solutions for the pharmaceutical and medical device industries. With the combined expertise of more than 600 researchers, market analysts and consultants, we deliver high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.
To find out more about how our research and consulting solutions can help you, please visit healthcare.globaldata.com
For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE's Top Pharma List - Methodology
Featured jobs
- Scientific Director – Medical Communications - New York or Remot...
-
$100000 - $150000
- Associate Director – Social Healthcare – London
-
HIGHLEY COMPETATIVE SALARY, BONUS &BENEFITS
- EU Head of Business Development and Client Service
-
Exceptional packge and bonus
- Account Manager, Medical Communications and Marketing
-
£30, 000 – £40, 000 benefits and bonus
-
Senior Medical Writer
-
Salary TBC
-
Account Director, Medical Education
-
Salary TBC
- Freelance AM/ AD Healthcare Advertising
-
£350-400 depending on experience
- Scientific Director – Medical Communications
-
Salary TBC
-
Creative/ Medical Writer
-
Circa £35, 000 With Benefits
- Senior Account Manager, Medical Communications, London
-
Excellent package
-
Digital Account Director
-
Salary TBC
- Home based, Senior Medical Writer, Medical Communications
-
Excellent package
- Science Writer, Healthcare Advertising Agency
-
£40, 000 - 45, 000 DOE benefits,
- Freelance Senior Account Manager / Account Director - Healthcare...
-
£350-400 depending on experience
Subscribe to our email news alerts
- NHS needs £900m a year to avoid crippling staff shortages
- Leading Edge, a Lucid Group company, strengthens its senior clients services team
- Quick Change
- From Cowgirl to Medical Writer - How did that happen?
- Pfizer hedges bets on gene therapy deal
- Three amazing women at emotive. talk about what they love about medical communications
PMHub
Syneos Health™
Syneos Health™ is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract...
Latest intelligence
- Brain power: fresh approaches to Alzheimer’s drug discovery
- New alliances are learning from past mistakes and breaking down research barriers...
- Genomics integration: can the NHS rise to the challenge?
- Experts gather to discuss the UK’s genomic landscape...
- “Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
- The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...
Quick links
Infographics
